{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T20:31:55Z","timestamp":1788294715629,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12882-017-0605-7","type":"journal-article","created":{"date-parts":[[2017,6,30]],"date-time":"2017-06-30T12:40:40Z","timestamp":1498826440000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events and residual renal function in dialysis patients: a meta-analysis of randomised controlled trials"],"prefix":"10.1186","volume":"18","author":[{"given":"Youxia","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junya","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiekun","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,30]]},"reference":[{"key":"605_CR1","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/j.ajkd.2009.10.009","volume":"55","author":"AJ Collins","year":"2010","unstructured":"Collins AJ, Foley RN, Herzog C, Chavers BM, Gilbertson D, Ishani A, et al. Excerpts from the US renal data system 2009 annual data report. Am J Kidney Dis. 2010;55:S1\u2013420. A6-7","journal-title":"Am J Kidney Dis"},{"key":"605_CR2","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1161\/01.HYP.0000102971.85504.7c","volume":"42","author":"MJ Sarnak","year":"2003","unstructured":"Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Hypertension. 2003;42:1050\u201365.","journal-title":"Hypertension"},{"key":"605_CR3","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1053\/ajkd.2001.25198","volume":"38","author":"D Shemin","year":"2001","unstructured":"Shemin D, Bostom AG, Laliberty P, Dworkin LD. Residual renal function and mortality risk in hemodialysis patients. Am J Kidney Dis. 2001;38:85\u201390.","journal-title":"Am J Kidney Dis"},{"key":"605_CR4","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1093\/ndt\/gfq856","volume":"26","author":"WM Wal van der","year":"2011","unstructured":"van der Wal WM, Noordzij M, Dekker FW, Boeschoten EW, Krediet RT, Korevaar JC, et al. Full loss of residual renal function causes higher mortality in dialysis patients; findings from a marginal structural model. Nephrol Dial Transplant. 2011;26:2978\u201383.","journal-title":"Nephrol Dial Transplant"},{"key":"605_CR5","doi-asserted-by":"crossref","first-page":"629","DOI":"10.7326\/0003-4819-134-8-200104170-00007","volume":"134","author":"JF Mann","year":"2001","unstructured":"Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med. 2001;134:629\u201336.","journal-title":"Ann Intern Med"},{"key":"605_CR6","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1681\/ASN.2007020256","volume":"18","author":"V Perkovic","year":"2007","unstructured":"Perkovic V, Ninomiya T, Arima H, Gallagher M, Jardine M, Cass A, et al. Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: data from the PROGRESS study. J Am Soc Nephrol. 2007;18:2766\u201372.","journal-title":"J Am Soc Nephrol"},{"key":"605_CR7","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1053\/j.ajkd.2015.10.011","volume":"67","author":"X Xie","year":"2016","unstructured":"Xie X, Liu Y, Perkovic V, Li X, Ninomiya T, Hou W, et al. Renin-Angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials. Am J Kidney Dis. 2016;67:728\u201341.","journal-title":"Am J Kidney Dis"},{"key":"605_CR8","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1093\/ndt\/gfl293","volume":"21","author":"A Takahashi","year":"2006","unstructured":"Takahashi A, Takase H, Toriyama T, Sugiura T, Kurita Y, Ueda R, et al. Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis--a randomized study. Nephrol Dial Transplant. 2006;21:2507\u201312.","journal-title":"Nephrol Dial Transplant"},{"key":"605_CR9","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/sj.ki.5001657","volume":"70","author":"F Zannad","year":"2006","unstructured":"Zannad F, Kessler M, Lehert P, Grunfeld JP, Thuilliez C, Leizorovicz A, et al. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int. 2006;70:1318\u201324.","journal-title":"Kidney Int"},{"key":"605_CR10","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1053\/j.ajkd.2008.04.031","volume":"52","author":"H Suzuki","year":"2008","unstructured":"Suzuki H, Kanno Y, Sugahara S, Ikeda N, Shoda J, Takenaka T, et al. Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial. Am J Kidney Dis. 2008;52:501\u20136.","journal-title":"Am J Kidney Dis"},{"key":"605_CR11","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1053\/j.ajkd.2014.05.011","volume":"64","author":"KD Kjaergaard","year":"2014","unstructured":"Kjaergaard KD, Peters CD, Jespersen B, Tietze IN, Madsen JK, Pedersen BB, et al. Angiotensin blockade and progressive loss of kidney function in hemodialysis patients: a randomized controlled trial. Am J Kidney Dis. 2014;64:892\u2013901.","journal-title":"Am J Kidney Dis"},{"key":"605_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols PRISMA-P 2015 statement. Syst Rev. 2015;4:1.","journal-title":"Syst Rev"},{"key":"605_CR13","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924\u20136.","journal-title":"BMJ"},{"key":"605_CR14","doi-asserted-by":"crossref","first-page":"105","DOI":"10.7326\/0003-4819-139-2-200307150-00010","volume":"139","author":"PK Li","year":"2003","unstructured":"Li PK, Chow KM, Wong TY, Leung CB, Szeto CC. Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. Ann Intern Med. 2003;139:105\u201312.","journal-title":"Ann Intern Med"},{"key":"605_CR15","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1053\/j.ajkd.2004.01.019","volume":"43","author":"H Suzuki","year":"2004","unstructured":"Suzuki H, Kanno Y, Sugahara S, Okada H, Nakamoto H. Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. Am J Kidney Dis. 2004;43:1056\u201364.","journal-title":"Am J Kidney Dis"},{"key":"605_CR16","first-page":"605","volume":"4","author":"J Wang","year":"2005","unstructured":"Wang J, Xiao MY. Protective effects of Vaisartan on residual renal function in patients on CAPD. Chin J Blood Purif. 2005;4:605\u20136.","journal-title":"Chin J Blood Purif"},{"key":"605_CR17","first-page":"413","volume":"23","author":"H Zhong","year":"2007","unstructured":"Zhong H, Sha CH, Cui TL, et al. Effects of irbesartan on residual renal function in peritoneal dialysis patients. Chin J Nephrol. 2007;23:413\u20136.","journal-title":"Chin J Nephrol"},{"key":"605_CR18","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3109\/0886022X.2010.502276","volume":"32","author":"R Yilmaz","year":"2010","unstructured":"Yilmaz R, Altun B, Kahraman S, Ozer N, Akinci D, Turgan C. Impact of amlodipine or ramipril treatment on left ventricular mass and carotid intima-media thickness in nondiabetic hemodialysis patients. Ren Fail. 2010;32:903\u201312.","journal-title":"Ren Fail"},{"key":"605_CR19","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1093\/ndt\/gfs590","volume":"28","author":"K Iseki","year":"2013","unstructured":"Iseki K, Arima H, Kohagura K, Komiya I, Ueda S, Tokuyama K, et al. Effects of angiotensin receptor blockade ARB on mortality and cardiovascular outcomes in patients with long-term haemodialysis: a randomized controlled trial. Nephrol Dial Transplant. 2013;28:1579\u201389.","journal-title":"Nephrol Dial Transplant"},{"key":"605_CR20","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/ndt\/gft515","volume":"29","author":"R Agarwal","year":"2014","unstructured":"Agarwal R, Sinha AD, Pappas MK, Abraham TN, Tegegne GG. Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial. Nephrol Dial Transplant. 2014;29:672\u201381.","journal-title":"Nephrol Dial Transplant"},{"key":"605_CR21","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1056\/NEJM197403282901301","volume":"290","author":"A Lindner","year":"1974","unstructured":"Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med. 1974;290:697\u2013701.","journal-title":"N Engl J Med"},{"key":"605_CR22","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1093\/eurheartj\/eht065","volume":"34","author":"W Hou","year":"2013","unstructured":"Hou W, Lv J, Perkovic V, Yang L, Zhao N, Jardine MJ, et al. Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. Eur Heart J. 2013;34:1807\u201317.","journal-title":"Eur Heart J"},{"key":"605_CR23","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/sj.ki.5001542","volume":"70","author":"ML Melamed","year":"2006","unstructured":"Melamed ML, Eustace JA, Plantinga L, Jaar BG, Fink NE, Coresh J, et al. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. Kidney Int. 2006;70:351\u20137.","journal-title":"Kidney Int"},{"key":"605_CR24","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/ndt\/gfp395","volume":"25","author":"R Paniagua","year":"2010","unstructured":"Paniagua R, Ventura MD, Avila-Diaz M, Hinojosa-Heredia H, Mendez-Duran A, Cueto-Manzano A, et al. NT-proBNP, fluid volume overload and dialysis modality are independent predictors of mortality in ESRD patients. Nephrol Dial Transplant. 2010;25:551\u20137.","journal-title":"Nephrol Dial Transplant"},{"key":"605_CR25","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1046\/j.1523-1755.1999.00422.x","volume":"55","author":"P Stenvinkel","year":"1999","unstructured":"Stenvinkel P, Heimburger O, Paultre F, Diczfalusy U, Wang T, Berglund L, et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 1999;55:1899\u2013911.","journal-title":"Kidney Int"},{"key":"605_CR26","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.jelectrocard.2016.07.016","volume":"49","author":"D Banerjee","year":"2016","unstructured":"Banerjee D. Sudden cardiac death in haemodialysis: clinical epidemiology and mechanisms. J Electrocardiol. 2016;49:843\u20137.","journal-title":"J Electrocardiol"},{"key":"605_CR27","first-page":"776","volume":"19","author":"M Anees","year":"2009","unstructured":"Anees M, Ibrahim M. Anemia and hypoalbuminemia at initiation of hemodialysis as risk factor for survival of dialysis patients. J Coll Physicians Surg Pak. 2009;19:776\u201380.","journal-title":"J Coll Physicians Surg Pak"},{"key":"605_CR28","first-page":"315","volume":"64","author":"FA Reyes-Marin","year":"2012","unstructured":"Reyes-Marin FA, Calzada C, Ballesteros A, Amato D. Comparative study of enalapril vs. losartan on residual renal function preservation in automated peritoneal dialysis. A randomized controlled study. Rev Investig Clin. 2012;64:315\u201321.","journal-title":"Rev Investig Clin"},{"key":"605_CR29","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1210\/en.2003-0150","volume":"144","author":"JL Lavoie","year":"2003","unstructured":"Lavoie JL, Sigmund CD. Minireview: overview of the renin-angiotensin system--an endocrine and paracrine system. Endocrinology. 2003;144:2179\u201383.","journal-title":"Endocrinology"},{"key":"605_CR30","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0002-9343(01)01068-3","volume":"112","author":"GA Knoll","year":"2002","unstructured":"Knoll GA, Sahgal A, Nair RC, Graham J, van Walraven C, Burns KD. Renin\u2013angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients. Am J Med. 2002;112:110\u20134.","journal-title":"Am J Med"},{"key":"605_CR31","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/sj.ki.5002745","volume":"736","author":"A Davenport","year":"2008","unstructured":"Davenport A, Cox C, Thuraisingham R. Achieving blood pressure targets during dialysis improves control but increases intradialytic hypotension. Kidney Int. 2008;736:759\u201364.","journal-title":"Kidney Int"},{"key":"605_CR32","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2215\/CJN.07831109","volume":"5","author":"DJ Tai","year":"2010","unstructured":"Tai DJ, Lim TW, James MT, Manns BJ, Tonelli M, Hemmelgarn BR. Cardiovascular effects of angiotensin converting enzyme inhibition or angiotensin receptor blockade in hemodialysis: a meta-analysis. Clin J Am Soc Nephrol. 2010;5:623\u201330.","journal-title":"Clin J Am Soc Nephrol"},{"key":"605_CR33","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1177\/089686080902900514","volume":"29","author":"A Akbari","year":"2009","unstructured":"Akbari A, Knoll G, Ferguson D, McCormick B, Davis A, Biyani M. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in peritoneal dialysis: systematic review and meta-analysis of randomized controlled trials. Perit Dial Int. 2009;29:554\u201361.","journal-title":"Perit Dial Int"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-017-0605-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,11]],"date-time":"2020-10-11T08:56:52Z","timestamp":1602406612000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-017-0605-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,30]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["605"],"URL":"https:\/\/doi.org\/10.1186\/s12882-017-0605-7","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,30]]},"article-number":"206"}}